Noile-Immune Biotech (TSE:4893) EPS (Basic): 円-7.50 (TTM As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
53 GF Score
Price 円119.00
GF Value 円4.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech EPS (Basic)?

Noile-Immune Biotech TSE:4893 +2.59% 53 EPS (Basic) is 円-7.50 as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.38 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Noile-Immune Biotech's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was 円0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-7.50.

Noile-Immune Biotech's EPS (Diluted) for the three months ended in Dec. 2025 was 円0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-7.50.

Noile-Immune Biotech's EPS without NRI for the three months ended in Dec. 2025 was 円0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -7.50.

During the past 3 years, the average EPS without NRI Growth Rate was -22.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Noile-Immune Biotech's highest 3-Year average EPS without NRI Growth Rate was -4.80% per year. The lowest was -24.60% per year. And the median was -22.90% per year.

Noile-Immune Biotech  (TSE:4893) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Noile-Immune Biotech EPS (Basic) Related Terms

Noile-Immune Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech EPS (Basic) Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -19.34 -9.87 -27.25 -22.28 -18.33

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -5.55 -3.96 0.00 -3.54
TSE:4893
53GF Score
Noile-Immune Biotech Inc TSE:4893
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Noile-Immune Biotech's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-793.536-0)/43.302
=-18.33

Noile-Immune Biotech's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0-0)/43.302
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-7.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円-7.50 mean?
Noile-Immune Biotech (TSE:4893) has a EPS (Basic) of 円-7.50 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's EPS (Basic) too high?
Noile-Immune Biotech's current EPS (Basic) is 円-7.50. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's EPS (Basic) compare to VRTX and REGN?
Noile-Immune Biotech's EPS (Basic) of 円-7.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current EPS (Basic) is 円-7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.38, compared to a current price of 円119.00 — trading 2616.9% above its estimated fair value. The current EPS (Basic) is 円-7.50. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current EPS (Basic) is 円-7.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円119.00 is trading 2616.9% above its estimated GF Value™ of 円4.38. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • EPS (Basic): 円-7.50
  • GF Value™: 円4.38 vs. price of 円119.00 (2616.9% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score

Get the complete analysis for TSE:4893

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円119.00
Price
円4.38
GF Value